Webinar: Evaluation of Checkpoint Inhibitor Therapies using a Mixed Lymphocyte Reaction (MLR) Assay
Immune checkpoints are signaling molecules which control the synapse between T cells and antigen presenting cells (APCs).
Checkpoint inhibitor therapies target and inhibit the signals that ‘switch off’ T cells, leading to an upregulation of T cell activation and tumor cell killing.
The mixed lymphocyte reaction (MLR) mimics the T cell and APC synapse by co-culturing immune cells from two individuals. MLR is used as a model, to explore the effects of checkpoint inhibitor drugs in vitro; facilitating biological research applications and drug discovery processes.
Key webinar discussion topics include:
- The impact of checkpoint inhibitor therapeutics on inflammatory cytokine release
- How the iQue® Advanced Flow Cytometry Platform and associated reagent kits can be used to quantify T cell response in MLR
- The use of the iQue® MLR assay to generate pharmacological outputs for checkpoint inhibitor induced T cell activation
About the speaker
iQue® Applications Group, Sartorius
Kirsty McBain is an Associate Scientist in the iQue® Applications Group, part of the European based BioAnalytics at Sartorius, where she is involved in the research and development of novel applications.
Kirsty’s efforts are focused on the iQue® 3 advanced flow cytometry platform where she has supported a number of the immuno-oncology campaigns that are used to exemplify how Sartorius technology can be applied to the drug discovery process. Kirsty obtained a master’s degree in Biochemistry at the University of Bristol before joining Sartorius in 2019.